Clinical Trial: FAPI PET in Systemic Sclerosis Interstitial Lung Disease

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07925242) titled 'FAPI PET in Systemic Sclerosis Interstitial Lung Disease' on Nov. 03.

Brief Summary: This is a phase II open-label efficacy and safety study to evaluate standard of care treatment response measured by PET imaging radiotracer 68Ga-FAPI-46 in 120 subjects with SSc-ILD.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Systemic Sclerosis (SSc) Scleroderma Interstitial Lung Disease With Systemic Sclerosis

Intervention: DRUG: FAPI tracer

68Ga-FAPI-46 will be used for the PET/CT for SSc ILD patients

Recruitment Status: NOT_YET_RECRUITING

Sponsor: University of California, Los Angeles

Information provided by (Res...